CTIC CTI BioPharma Corp.

0.82
+0.03  (+4%)
Previous Close 0.79
Open 0.82
Price To Book 1.17
Market Cap 47,501,969
Shares 57,978,725
Volume 54,995
Short Ratio
Av. Daily Volume 118,011
Stock charts supplied by TradingView

NewsSee all news

  1. CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia

    SEATTLE, Oct. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released July 9. 2018. Primary endpoint not met.
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
Phase 3 trial initiation announced October 1, 2019 with data due mid-2021.
Pacritinib - PACIFICA
Myelofibrosis
Phase 3 trial potentially in the pipeline.
Tosedostat
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
OPAXIO
Ovarian cancer

Latest News

  1. CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia

    SEATTLE, Oct. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment